Wordt geladen...
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...
Bewaard in:
| Gepubliceerd in: | Oncoimmunology |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5006894/ https://ncbi.nlm.nih.gov/pubmed/27622011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1052212 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|